Introduction

Moyamoya disease is a rare cerebrovascular condition characterized by the progressive narrowing or occlusion (blockage) of the blood vessels at the base of the brain. This chronic condition predisposes individuals to ischemic strokes, where blood flow to parts of the brain is restricted. However, one of the most severe complications of Moyamoya disease is hemorrhagic stroke, which occurs when a weakened blood vessel ruptures and causes bleeding into the brain. This article explores the intricate relationship between Moyamoya disease and hemorrhagic stroke, highlighting the mechanisms, risk factors, diagnosis, treatment options, and prognosis associated with this complex neurological condition.¹

Understanding Moyamoya disease

Moyamoya disease was first described in Japan and is named after the Japanese term meaning "puff of smoke," which aptly describes the appearance of the tiny collateral blood vessels that form to compensate for the blockage of the main arteries. The exact cause of Moyamoya disease remains unclear, although genetic factors are believed to play a significant role. It predominantly affects children and young adults but can also occur in older adults.¹

The hallmark of Moyamoya disease is the progressive narrowing or stenosis of the internal carotid arteries and their branches, which supply blood to the brain. As these arteries become occluded, the brain compensates by forming collateral blood vessels, often in a haphazard and fragile manner. These collateral vessels are prone to rupture, leading to hemorrhagic strokes, which tend to be a devastating complication of the disease.²

Mechanisms of hemorrhagic stroke in Moyamoya disease

Hemorrhagic stroke in Moyamoya disease typically occurs due to the fragility of the collateral blood vessels that develop in response to arterial stenosis. These vessels, termed Moyamoya vessels, are prone to weakening and rupture under the continuous pressure of blood flow. When a vessel ruptures, it causes bleeding into the brain parenchyma (intracerebral hemorrhage) or the surrounding spaces (subarachnoid hemorrhage), depending on the location of the rupture.²

The risk of hemorrhagic stroke is significantly higher in Moyamoya disease compared to the general population. Factors such as hypertension, ongoing ischemic insults, and the presence of aneurysms along the collateral vessels further increase the risk of vessel rupture and subsequent bleeding.²

Risk factors

Several factors contribute to the risk of developing Moyamoya disease and experiencing hemorrhagic stroke, including:³

• Genetic factors: Moyamoya disease has a genetic component, with several genes implicated in its development. However, the exact inheritance pattern remains complex
• Ethnicity: The disease is more prevalent in individuals of Asian descent, although cases have been reported worldwide
• Age: Moyamoya disease can occur at any age but is most commonly diagnosed in children and young adults
• Medical History: Conditions such as sickle cell disease, neurofibromatosis type 1, and Down syndrome are associated with an increased risk of Moyamoya disease

Diagnosis

Diagnosing Moyamoya disease involves a comprehensive approach, including a combination of clinical evaluation and imaging studies. For example:⁴

• Clinical evaluation: Symptoms such as recurrent transient ischemic attacks (TIAs), headaches, and seizures may prompt further investigation
• Imaging studies: Magnetic resonance angiography (MRA) and digital subtraction angiography (DSA) are the primary imaging modalities used to visualize the characteristic narrowing of the arteries and the development of collateral vessels

Early diagnosis is crucial as it allows for timely intervention to prevent stroke and manage symptoms effectively.

Treatment options

The management of Moyamoya disease aims to prevent stroke, alleviate symptoms, and preserve neurological function. Treatment options include:⁵

• Surgical revascularization: Direct bypass procedures, such as superficial temporal artery to middle cerebral artery (STA-MCA) bypass or indirect procedures like encephalo-duro-arterio-synangiosis (EDAS), aim to improve blood flow to the affected areas of the brain and reduce the risk of stroke
• Medical management: Controlling risk factors such as hypertension and diabetes is essential to minimize the risk of stroke. Antiplatelet therapy may be considered in some cases to reduce the risk of thrombotic events
• Monitoring and supportive care: Regular imaging studies and neurological assessments are recommended to monitor disease progression and adjust treatment strategies accordingly

Prognosis

The prognosis for individuals with Moyamoya disease varies depending on several factors, including the severity of arterial occlusion, the presence of symptoms, and the timing of intervention. Early diagnosis and prompt treatment can significantly improve outcomes by reducing the risk of stroke and preserving neurological function. However, untreated or poorly managed Moyamoya disease carries a high risk of recurrent strokes and progressive neurological decline.⁶

Summary

Moyamoya disease is a complex cerebrovascular condition characterized by progressive arterial stenosis and the development of fragile collateral vessels in the brain. While ischemic stroke is a common complication, hemorrhagic stroke represents a severe and potentially life-threatening consequence of this disease. Understanding the mechanisms, risk factors, diagnosis, treatment options, and prognosis associated with Moyamoya disease and hemorrhagic stroke is crucial for optimizing patient care and improving outcomes for individuals affected by this rare neurological condition.

Continued research into the genetic and environmental factors contributing to Moyamoya disease, as well as advancements in surgical techniques and medical management, holds promise for enhancing our understanding and treatment of this challenging condition. By raising awareness and fostering interdisciplinary collaboration, we can strive towards better outcomes and quality of life for patients with Moyamoya disease and reduce the burden of stroke-related disability worldwide.